Review

Polylactic-co-glycolic acid-based nanoparticles modified with peptides and other linkers cross the blood–brain barrier for targeted drug delivery

Key Laboratory of Photochemistry Biomaterials & Energy Storage Materials of Heilongjiang Province, College of Chemistry & Chemical Engineering, Harbin Normal University, Harbin, Heilongjiang, 150025, China

‡Authors contributed equally

Search for more papers by this author

Ning Zhang‡

College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, China

Wuxi Traditional Chinese Medicine Hospital, Wuxi, Jiangsu, 214071, China

‡Authors contributed equally

Search for more papers by this author

Xinyu Zhong

Search for more papers by this author

Jinlian Gu

Search for more papers by this author

Chang Yan

Search for more papers by this author

Shun Yin

Search for more papers by this author

Xia Lei

Wuxi Traditional Chinese Medicine Hospital, Wuxi, Jiangsu, 214071, China

Search for more papers by this author

Jihui Zhao

College of Pharmacy, Hunan University of Medicine, Huaihua, Hunan, 418000, China

Search for more papers by this author

Fang Geng

*Author for correspondence:

E-mail Address: f.geng@hrbnu.edu.cn

Search for more papers by this author

Published Online:14 Mar 2023https://doi.org/10.2217/nnm-2022-0287

View article

Abstract

Because of the blood–brain barrier, only a limited fraction of drugs can penetrate the brain. As a result, there is a need to take larger doses of the drug, which may result in numerous undesirable side effects. Over the past few decades, a plethora of research has been conducted to address this issue. In recent years, the field of nanomedicine research has reported promising findings. Currently, numerous types of polylactic-co-glycolic acid-based drug-delivery systems are being studied, and great progress has been made in the modification of their surfaces with a variety of ligands. In this review, the authors highlight the preparation of polylactic-co-glycolic acid-based nanoparticles and single- and dual-targeted peptide modifications for site-specific drug delivery into the brain.

Plain language summary

The blood–brain barrier prevents many drugs used to treat brain diseases from having clinical effects. To solve this issue, some promising findings have been reported in the field of nanomedicine research, which will be introduced in this article as possible effective methods for the treatment of brain diseases. This review will focus on the nature of the polylactic-co-glycolic acid polymers involved in the preparation of desired targeted nanocarriers, the synthesis methods for achieving the drug loaded system and the choice and preparation of the targeting agents.

Tweetable abstract

This review comprehensively highlights the current research progress of modified polylactic-co-glycolic acid-based nanoparticles for brain-targeted drug delivery and concludes with a discussion on current challenges faced and future perspective.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Ayub A, Wettig S. An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics 14(2), 224 (2022). • Provides a comprehensive overview of rational design for crossing the blood–brain barrier (BBB) with nanoparticles (NPs).
Medline CASGoogle Scholar
2. Lombardo SM, Schneider M, Tureli AE, Tureli NG. Key for crossing the BBB with nanoparticles: the rational design. Beilstein J. Nanotechnol. 11(1), 866–883 (2020).
Medline CASGoogle Scholar
3. Furtado D, Bjrnmalm M, Ayton S et al. Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases. Adv. Mater. 30(46), 1801362 (2018).
Google Scholar
4. Markowicz Piasecka M, Markiewicz A, Darlak P et al. Current chemical, biological, and physiological views in the development of successful brain-targeted pharmaceutics. Neurotherapeutics 19(3), 942–976 (2022). •• Exhaustively reviews the most recent advances in nanocarrier-based drug delivery to the CNS.
MedlineGoogle Scholar
5. Mulvihill JJE, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers. Nanomedicine (Lond.) 15(2), 205–214 (2020).
CASGoogle Scholar
6. Xie JB, Shen ZY, Anraku Y, Kataoka K, Chen XY. Nanomaterial-based blood–brain-barrier (BBB) crossing strategies. Biomaterials 224, 119491 (2019).
Medline CASGoogle Scholar
7. Santos SD, Xavier M, Leite DM et al. PAMAM dendrimers: blood–brain barrier transport and neuronal uptake after focal brain ischemia. J. Control. Rel. 291, 65–79 (2018).
Medline CASGoogle Scholar
8. Li J, Rothstein SN, Little SR, Edenborn HM, Meyer TY. The effect of monomer order on the hydrolysis of biodegradable poly(lactic-co-glycolic acid) repeating sequence copolymers. J. Am. Chem. Soc. 134(39), 16352–16359 (2018).
Google Scholar
9. Anthony C, Alexandra G, Laurent L, Benjamin D. PLGA-based nanoparticles for neuroprotective drug delivery in neurodegenerative diseases. Pharmaceutics 13, 1042 (2021).
MedlineGoogle Scholar
10. Dos Reis LG, Lee WH, Svolos M et al. Nanotoxicologic effects of PLGA nanoparticles formulated with a cell-penetrating peptide: searching for a safe pDNA delivery system for the lungs. Pharmaceutics 11(1), 12 (2019).
MedlineGoogle Scholar
11. Zhi KN, Raji B, Nookala AR et al. PLGA nanoparticle-based formulations to cross the blood–brain barrier for drug delivery: from R&D to cGMP. Pharmaceutics 13(4), 500 (2021).
Medline CASGoogle Scholar
12. Cui YX, Sun JJ, Hao WY et al. Dual-target peptide-modified erythrocyte membrane-enveloped PLGA nanoparticles for the treatment of glioma. Front. Oncol. 10, 563938 (2020).
MedlineGoogle Scholar
13. Ogawa K, Kato N, Kawakami S. Recent strategies for targeted brain drug delivery. Chem. Pharm. Bull. (Tokyo) 68(7), 567–582 (2020).
Medline CASGoogle Scholar
14. Diaz Perlas C, Oller Salvia B, Sanchez Navarro M, Teixido M, Giralt E. Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood–brain barrier transport. Chem. Sci. 9(44), 8409–8415 (2018).
MedlineGoogle Scholar
15. Gonzalez Pizarro R, Parrotta G, Vera R et al. Ocular penetration of fluorometholone-loaded PEG-PLGA nanoparticles functionalized with cell-penetrating peptides. Nanomedicine (Lond.) 14(23), 3089–3104 (2020).
Google Scholar
16. Khan AR, Yang XY, Fu MF, Zhai GX. Recent progress of drug nanoformulations targeting to brain. J. Control. Rel. 291, 37–64 (2018).
Medline CASGoogle Scholar
17. Shi XD, Sun YL, Shen LT. Preparation and in vivo imaging of a novel potential αvβ3 targeting PET/MRI dual-modal imaging agent. J. Radioanal. Nucl. Chem. 331(9), 3485–3494 (2022). •• Describes dual-targeting strategies and their impact on improving targeting specificity and therapeutic effects.
CASGoogle Scholar
18. Luo Y, Yang H, Zhou YF, Hu B. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. J. Control. Rel. 317, 195–215 (2020).
Medline CASGoogle Scholar
19. Yin MM, Zheng Y, Chen FL. Pyraclostrobin-loaded poly(lactic-co-glycolic acid) nanospheres: preparation and characteristics. J. Integr. Agric. 17(8), 1822–1832 (2018).
CASGoogle Scholar
20. Han SL, Wang WJ, Wang SF et al. Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages. Nanoscale 11(42), 20206–20220 (2019). • Discusses the use of polylactic-co-glycolic acid (PLGA) NPs for delivery of a biomacromolecular therapeutic.
Medline CASGoogle Scholar
21. Ding DW, Zhu QD. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater. Sci. Eng. C Mater. Biol. Appl. 92, 1041–1060 (2018).
Medline CASGoogle Scholar
22. Takeuchi I, Taniguchi Y, Tamura Y, Ochiai K, Makino K. Effects of L-leucine on PLGA microparticles for pulmonary administration prepared using spray drying: fine particle fraction and phagocytotic ratio of alveolar macrophages. Colloids Surf. A Physicochem. Eng. Asp. 537, 411–417 (2018).
CASGoogle Scholar
23. El Maghawry E, Tadros MI, Elkheshen SA, Abd Elbary A. Eudragit-S100 coated PLGA nanoparticles for colon targeting of etoricoxib: optimization and pharmacokinetic assessments in healthy human volunteers. Int. J. Nanomed. 15, 3965–3980 (2020).
MedlineGoogle Scholar
24. Ramezani M, Ramezani M, Hashemi M. Current strategies in the modification of PLGA-based gene delivery system. Curr. Med. Chem. 24(7), 728–739 (2018).
Google Scholar
25. Piacentini E, Russo B, Bazzarelli F, Giorno L. Membrane nanoprecipitation: from basics to technology development. J. Membr. Sci. 654, 120564 (2022).
CASGoogle Scholar
26. Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater. 73, 38–51 (2018).
Medline CASGoogle Scholar
27. Rezvantalab S, Drude NI, Moraveji MK et al. PLGA-based nanoparticles in cancer treatment. Front. Pharmacol. 9, 1260 (2018).
Medline CASGoogle Scholar
28. Wei H, Zhang CM. Tuning the size of poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles fabricated by nanoprecipitation. Biotechnol. J. 13(1), 10.1002/biot.201700203 (2018).
Google Scholar
29. Zhou X, Smith QR, Liu XL. Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 13(4), e1695 (2021).
MedlineGoogle Scholar
30. Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20(1), 26–41 (2019).
MedlineGoogle Scholar
31. Dong XW. Current strategies for brain drug delivery. Theranostics 8(6), 1481–1493 (2018).
Medline CASGoogle Scholar
32. Li S, Xu Q, Zhao L et al. Angiopep-2 modified cationic lipid-poly-lactic-co-glycolic acid delivery temozolomide and DNA repair inhibitor Dbait to achieve synergetic chemo-radiotherapy against glioma. J. Nanosci. Nanotechnol. 19(12), 7539–7545 (2019).
Medline CASGoogle Scholar
33. Zhang L, Liu XG, Liu QD et al. A conditionally releasable ‘do not eat me’ CD47 signal facilitates microglia‐targeted drug delivery for the treatment of Alzheimer's disease. Adv. Funct. Mater. 30(24), 1910691 (2020).
CASGoogle Scholar
34. Huang N, Lu S, Liu XG, Zhu J, Wang YJ, Liu RT. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice. Oncotarget 8(46), 81001–81013 (2017).
MedlineGoogle Scholar
35. Falanga AP, Melone P, Cagliani R et al. Design, synthesis and characterization of novel co-polymers decorated with peptides for the selective nanoparticle transport across the cerebral endothelium. Molecules 23(7), 1655 (2018).
MedlineGoogle Scholar
36. Kang T, Jiang MY, Jiang D et al. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol. Pharm. 12(8), 2947–2961 (2015).
Medline CASGoogle Scholar
37. Hua HC, Zhang XM, Mu HJ et al. RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy. Int. J. Pharm. 543(1–2), 179–189 (2018).
Medline CASGoogle Scholar
38. Grover A, Hirani A, Pathak Y, Sutariya V. Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS PharmSciTech 15(6), 1562–1568 (2014). • Provides a comprehensive overview of NPs based on peptides and designed using the emerging principles of molecular engineering for efficient brain delivery.
Medline CASGoogle Scholar
39. Li J, Zhang C, Li J et al. Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides. Pharm. Res. 30(7), 1813–1823 (2013).
Medline CASGoogle Scholar
40. Ilyas S, Ullah NK, Ilyas M et al. Mediating the fate of cancer cell uptake: dual-targeted magnetic nanovectors with biotin and folate surface ligands. ACS Biomater. Sci. Eng. 6(11), 6138–6147 (2020).
Medline CASGoogle Scholar
41. Chen Q, Gong T, Liu J et al. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J. Drug Target. 17(4), 318–328 (2009).
Medline CASGoogle Scholar
42. Gynther M, Puris E, Peltokangas S et al. Alzheimer's disease phenotype or inflammatory insult does not alter function of L-type amino acid transporter 1 in mouse blood–brain barrier and primary astrocytes. Pharm. Res. 36(1), 17 (2019).
Google Scholar
43. Veszelka S, Meszaros M, Porkolab G et al. A triple combination of targeting ligands increases the penetration of nanoparticles across a blood–brain barrier culture model. Pharmaceutics 14(1), 86 (2021).
MedlineGoogle Scholar
44. Hoyos Ceballos GP, Ruozi B, Ottonelli I et al. PLGA-PEG-ANG-2 nanoparticles for blood–brain barrier crossing: proof-of-concept study. Pharmaceutics 12(1), 72 (2020).
MedlineGoogle Scholar
45. Sarkar G, Curran GL, Mahlum E et al. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLOS ONE 6(12), e28881 (2012).
Google Scholar
46. Kazdal F, Bahadori F, Celik B, Ertas A, Topcu G. Inhibition of amyloid aggregation using optimized nano-encapsulated formulations of plant extracts with high metal chelator activities. Curr. Pharm. Biotechnol. 21(8), 681–701 (2020).
Medline CASGoogle Scholar
47. Han HL, Zhang Y, Jin SZ et al. Paclitaxel-loaded dextran nanoparticles decorated with RVG29 peptide for targeted chemotherapy of glioma: an in vivo study. New J. Chem. 44(15), 5692–5701 (2020).
CASGoogle Scholar
48. Wei XL, Zhan CY, Shen Q et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew. Chem. Int. Ed. Engl. 54(10), 3066–3070 (2015).
Google Scholar
49. Chai ZL, Hu XF, Wei XL et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J. Control. Rel. 264, 102–111 (2017).
Medline CASGoogle Scholar
50. Geldenhuys W, Wehrung D, Groshev A, Hirani A, Sutariya V. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm. Dev. Technol. 20(4), 497–506 (2015).
Medline CASGoogle Scholar
51. Weng HH, Bejjanki NK, Zhang J et al. TAT peptide-modified cisplatin-loaded iron oxide nanoparticles for reversing cisplatin-resistant nasopharyngeal carcinoma. Biochem. Biophys. Res. Commun. 511(3), 597–603 (2019).
Medline CASGoogle Scholar
52. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 34(4), 1270–1280 (2012).
MedlineGoogle Scholar
53. Ruczynski J, Rusiecka I, Turecka K et al. Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin. Sci. Rep. 9(1), 3247 (2019).
MedlineGoogle Scholar
54. Vasudevan SM, Ashwanikumar N, Kumar GSV. Peptide decorated glycolipid nanomicelles for drug delivery across the blood–brain barrier (BBB). Biomater. Sci. 7(10), 4017–4021 (2019).
MedlineGoogle Scholar
55. Li JW, Feng L, Fan L et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32(21), 4943–4950 (2011).
Medline CASGoogle Scholar
56. Kuo YC, Lin PI, Wang CC. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine (Lond.) 6(6), 1011–1026 (2011).
CASGoogle Scholar
57. Liu ZD, Zhao HN, Shu LX et al. Preparation and evaluation of baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB. Drug Dev. Ind. Pharm. 41(3), 353–361 (2015).
Medline CASGoogle Scholar
58. Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody–iduronidase fusion protein. Mol. Pharm. 14(4), 1271–1277 (2017). •• Provides a comprehensive overview of ligand design and functionalization strategies for active targeting and drug delivery.
Medline CASGoogle Scholar
59. Koch H, Weber YG. The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav. 91, 90–93 (2019).
MedlineGoogle Scholar
60. Li WP, Zhang L, Shen YF, Du JM. Research process of glucose transporter 1 in Alzheimer's disease. China Med. Her. 14(14), 36–39 (2017).
Google Scholar
61. Peura L, Malmioja K, Huttunen K et al. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. Pharm. Res. 30(10), 2523–2537 (2013).
Medline CASGoogle Scholar
62. Puris E, Gynther M, Huttunen J, Petsalo A, Huttunen KM. L-type amino acid transporter 1 utilizing prodrugs: how to achieve effective brain delivery and low systemic exposure of drugs. J. Control. Rel. 261, 93–104 (2017).
Medline CASGoogle Scholar
63. Hansen SN, Tveden Nyborg P, Lykkesfeldt J. Does vitamin C deficiency affect cognitive development and function? Nutrients 6(9), 3818–3846 (2014).
Medline CASGoogle Scholar
64. Dehaini D, Fang RH, Zhang LF. Biomimetic strategies for targeted nanoparticle delivery. Bioeng. Transl. Med. 1(1), 30–46 (2016).
MedlineGoogle Scholar
65. Huang YY, Zhao R. Targeted analysis of central nervous system using blood–brain barrier shuttle peptides. Chinese J. Anal. Chem. 47(10), 1629–1638 (2019).
CASGoogle Scholar
66. Linton MF, Tao H, Linton EF, Yancey PG. SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis. Trends Endocrinol. Metab. 28(6), 461–472 (2017).
Medline CASGoogle Scholar
67. Liu SL, Zhang W, Chen QQ et al. Multifunctional nanozyme for multimodal imaging-guided enhanced sonodynamic therapy by regulating the tumor microenvironment. Nanoscale 13(33), 14049–14066 (2021).
Medline CASGoogle Scholar
68. Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc. Res. 116(7), 1254–1274 (2020).
Medline CASGoogle Scholar
69. Zhang C, Liu QF, Shao XY, Qian Y, Zhang QZ. Phage-displayed peptide-conjugated biodegradable nanoparticles enhanced brain drug delivery. Mater. Lett. 167, 213–217 (2016).
CASGoogle Scholar
70. Sumbria RK. Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease. Neural Regen. Res. 15(12), 2251–2252 (2020).
Medline CASGoogle Scholar
71. Huey R, Hawthorne S, McCarron P. The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review. J. Drug Target. 25(5), 379–385 (2016).
MedlineGoogle Scholar
72. Hoskin JL, Al Hasan Y, Sabbagh MN. Nicotinic acetylcholine receptor agonists for the treatment of Alzheimer's dementia: an update. Nicotine Tob. Res. 21(3), 370–376 (2019).
MedlineGoogle Scholar
73. Chung EP, Cotter JD, Prakapenka AV et al. Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-modified PLGA nanoparticles. Pharmaceutics 12(2), 93 (2020).
Medline CASGoogle Scholar
74. Mogharbel BF, Cardoso MA, Irioda AC et al. Biodegradable nanoparticles loaded with levodopa and/or curcumin for treatment of Parkinson's disease. Eur. J. Public Health 31(Suppl. 2), ckab120.070 (2021).
Google Scholar
75. Duro Castano A, Leite DM, Forth J et al. Designing peptide nanoparticles for efficient brain delivery. Adv. Drug Deliv. Rev. 160(72), 52–77 (2020).
MedlineGoogle Scholar
76. Kitamatsu M, Yuasa H, Ohtsuki T, Michiue H. Complementary leucine zippering system for effective intracellular delivery of proteins by cell-penetrating peptides. Bioorg. Med. Chem. 33, 116036 (2021).
Medline CASGoogle Scholar
77. Jank L, Pinto Espinoza C, Duan YH, Koch Nolte F, Magnus T, Rissiek B. Current approaches and future perspectives for nanobodies in stroke diagnostic and therapy. Antibodies (Basel) 8(1), 5 (2019).
Medline CASGoogle Scholar
78. Alecou T, Giannakou MA, Damianou C. Amyloid β plaque reduction with antibodies crossing the blood–brain barrier, which was opened in 3 sessions of focused ultrasound in a rabbit model. J. Ultrasound Med. 36(11), 2257–2270 (2017).
MedlineGoogle Scholar
79. Carroll RT, Bhatia D, Geldenhuys W et al. Brain-targeted delivery of tempol-loaded nanoparticles for neurological disorders. J. Drug Target. 18(9), 665–674 (2010).
Medline CASGoogle Scholar
80. Zhang WD, Liu QY, Haqqani AS et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS 17(1), 47 (2020).
Medline CASGoogle Scholar
81. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev. 42(3), 1147–1235 (2013).
Medline CASGoogle Scholar
82. Chen JF, Jin J, Li KQ et al. Progresses and prospects of neuroprotective agents-loaded nanoparticles and biomimetic material in ischemic stroke. Front. Cell. Neurosci. 11(16), 868323 (2022).
Google Scholar
83. Li CW, Qian JW, Chu YW. Advances in brain delivery systems based on biomimetic nanoparticles. ChemNanoMat 8(6), e202200066 (2022).
CASGoogle Scholar
84. Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat. Rev. Cancer 14(10), 683–691 (2014).
Medline CASGoogle Scholar
85. Li R, He Y, Zhang S, Qin J, Wang J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm. Sin. B 8(1), 14–22 (2017).
Medline CASGoogle Scholar
86. Fan Z, Li PY, Deng J, Bady SC, Cheng H. Cell membrane coating for reducing nanoparticle-induced inflammatory responses to scaffold constructs. Nano Res. 11(10), 5573–5583 (2018).
Medline CASGoogle Scholar
87. Tan S, Wu T, Zhang D, Zhang Z. Cell or cell membrane-based drug delivery systems. Theranostics 5(8), 863–881 (2015).
Medline CASGoogle Scholar
88. Song F, Chan WCW. Principles of conjugating quantum dots to proteins via carbodiimide chemistry. Nanotechnology 22(49), 494006 (2011).
MedlineGoogle Scholar
89. Werengowska Ciecwierz K, Wisniewski M, Terzyk AP, Furmaniak S. The chemistry of bioconjugation in nanoparticles-based drug delivery system. Adv. Condens. Matter Phys. 2015, 198175 (2015).
Google Scholar
90. Liu YY, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120(12), 2527–2537 (2007).
Medline CASGoogle Scholar
91. Xu HK, Zhang YP, Wan C et al. A bifunctional vinyl-sulfonium tethered peptide induced by thio-Michael-type addition reaction. Chin. Chem. Lett. 33(4), 2001–2004 (2022).
CASGoogle Scholar
92. Algar WR, Prasuhn DE, Stewart MH et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug. Chem. 22(5), 825–858 (2011).
Medline CASGoogle Scholar
93. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem Int. Ed. 40(11), 2004–2021 (2001).
Medline CASGoogle Scholar
94. Hoyle CE, Bowman CN. Thiol-ene click chemistry. Angew. Chem. Int. Ed. Engl. 49(9), 1540–1573 (2010).
Medline CASGoogle Scholar
95. Gregoritza M, Brandl FP. The Diels–Alder reaction: a powerful tool for the design of drug delivery systems and biomaterials. Eur. J. Pharm. Biopharm. 97, 438–453 (2015).
Medline CASGoogle Scholar
96. Hein CD, Liu XM, Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm. Res. 25(10), 2216–2230 (2008).
Medline CASGoogle Scholar
97. Yoon HY, Lee D, Lim DK, Koo H, Kim K. Copper-free click chemistry: applications in drug delivery, cell tracking, and tissue engineering. Adv. Mater. 34(10), 2107192 (2022).
CASGoogle Scholar
98. Kim E, Koo H. Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo. Chem. Sci. 10(34), 7835–7851 (2019).
Medline CASGoogle Scholar
99. Gao H, Yang Z, Zhang S et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep. 3, 2534 (2013).
Medline CASGoogle Scholar
100. Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm. Res. 30(10), 2485–2498 (2013).
Medline CASGoogle Scholar
101. Gao H. Perspectives on dual targeting delivery systems for brain tumors. J. Neuroimmune Pharmacol. 12(1), 6–16 (2017).
MedlineGoogle Scholar
102. Talekar M, Trivedi M, Shah P et al. Combination wt-p53 and microRNA-125b transfection in a genetically engineered lung cancer model using dual CD44/EGFR-targeting nanoparticles. Mol. Ther. 24(4), 759–769 (2016).
Medline CASGoogle Scholar
103. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 31(3), 326–341 (2017).
Medline CASGoogle Scholar
104. Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol. Pharm. 11(3), 1042–1052 (2014).
Medline CASGoogle Scholar
105. Dixit S, Miller K, Zhu Y et al. Dual receptor-targeted theranostic nanoparticles for localized delivery and activation of photodynamic therapy drug in glioblastomas. Mol. Pharm. 12(9), 3250–3260 (2015).
Medline CASGoogle Scholar
106. Xu C, Sun Y, Yu Y, Hu M, Yang C, Zhang Z. A sequentially responsive and structure-transformable nanoparticle with comprehensively improved ‘CAPIR cascade’ for enhanced antitumor effect. Nanoscale 11(3), 1177–1194 (2018).
Google Scholar
107. Chen WH, Luo GF, Qiu WX et al. Programmed nanococktail for intracellular cascade reaction regulating self-synergistic tumor targeting therapy. Small 12(6), 733–744 (2016).
Medline CASGoogle Scholar
108. Mendes M, Sousa JJ, Pais A, Vitorino C. Targeted theranostic nanoparticles for brain tumor treatment. Pharmaceutics 10(4), 181 (2018).
Medline CASGoogle Scholar
109. Zhang C, Zheng X, Wan X et al. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease. J. Control. Rel. 192, 317–324 (2014).
Medline CASGoogle Scholar
110. Kim KS, Suzuki K, Cho H, Youn YS, Bae YH. Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport. ACS Nano 12(9), 8893–8900 (2018).
Medline CASGoogle Scholar
111. Loureiro JA, Gomes B, Fricker G et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. Colloids Surf. B Biointerfaces 145, 8–13 (2016).
Medline CASGoogle Scholar

Vol. 18, No. 2

Metrics

Downloaded 170 times

History

Received 8 November 2022

Accepted 6 February 2023

Published online 14 March 2023

Published in print January 2023

Information

Keywords

Author contributions

Y Na, N Zhang and F Geng were responsible for conceptualizing the study and writing the manuscript.X Zhong, J Gu, C Yan and S Yin were responsible for consulting the relevant literature and giving ideas. X Lei and J Zhao were responsible for reviewing and revising the manuscript.

Financial & competing interests disclosure

This work was supported by the National Natural Science Foundation of China (82174007). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download